Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Extended lamivudine treatment in patients affected by chronic active anti-Hbe positive hepatitis.

Journal of chemotherapy (Florence, Italy) - 1 Feb 2006

Scotto G, Palumbo E, Fazio V, Saracino A, Angarano G

Abstract excerpt

The aim of the study was to evaluate the biochemical and virological response and the histological changes in 34 chronic hepatitis B anti-Hbe-positive patients treated with lamivudine at 100 mg/day orally for five years. Liver biopsies were performed in all patients at least 6 months before starting therapy and 3 months after the stop of treatment. After 12 months of therapy, 70.6% of patients showed evidence of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Amino Acid Motifs
Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA, Viral

Share to Hepatitis B, Chronic

Share to Hepatitis B e Antigens

Share to Lamivudine

Share to Virus Replication

Source

Identifiers

PMID: 16572893
DOI: 10.1179/joc.2006.18.1.43

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Extended lamivudine treatment in patients affected by chronic active anti-Hbe positive hepatitis.PMID 16572893Read ↗

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.Semantic proximity Read ↗

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.Semantic proximity Read ↗

Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants.Semantic proximity Read ↗

Clinical features of chronic hepatitis B patients with YMDD mutation after lamivudine therapy.Semantic proximity Read ↗

Histological outcome during long-term lamivudine therapy.Semantic proximity Read ↗

Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.Semantic proximity Read ↗

Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B.Semantic proximity Read ↗

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.Semantic proximity Read ↗

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.Semantic proximity Read ↗

Determinants for sustained HBeAg response to lamivudine therapy.Semantic proximity Read ↗

Prognosis of 153 patients with decompensated hepatitis B virus-related cirrhosis is improved after 3-year continuous lamivudine treatment.Semantic proximity Read ↗

HBV-DNA suppression and disease course in HBV cirrhosis patients on long-term lamivudine therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.